POLYNOVO LIMITED (PNV)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PNV - POLYNOVO LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -4.11
Index: ASX200 | ASX300 | ALL-ORDS

PolyNovo is an Australian medical devices company developing and commercialising its NovoSorb technology for the treatment of burns, wounds and negative pressure wound therapy. It has been a listed company since 1998.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.56

25 Jul
2024

-0.110

OPEN

$2.62

-4.12%

HIGH

$2.62

1,949,830

LOW

$2.53

TARGET
$2.075 -18.9% downside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PER . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
PNV: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx - 0.7 0.9 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 303.5 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-0.7
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx65.2 M
Book Value Per Share xxxxxxxxxxxxxxx9.5
Net Operating Cash Flow xxxxxxxxxxxxxxx-5.9 M
Net Profit Margin xxxxxxxxxxxxxxx-7.55 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-11.85 %
Return on Invested Capital xxxxxxxxxxxxxxx-9.25 %
Return on Assets xxxxxxxxxxxxxxx-7.72 %
Return on Equity xxxxxxxxxxxxxxx-11.85 %
Return on Total Capital xxxxxxxxxxxxxxx-11.23 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-7.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx2 M
Long Term Debt xxxxxxxxxxxxxxx14 M
Total Debt xxxxxxxxxxxxxxx16 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx47 M
Price To Book Value xxxxxxxxxxxxxxx16.31

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx1.5 M
Capex % of Sales xxxxxxxxxxxxxxx2.34 %
Cost of Goods Sold xxxxxxxxxxxxxxx46 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx26 M
Research & Development xxxxxxxxxxxxxxx7 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.3

No. Of Recommendations

4
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

09/05/2024

5

Sell

$1.00

-60.94%

Ord Minnett believes shares in PolyNovo look 'overvalued' in light of the slowing in sales growth momentum as has become apparent in the biotech's latest market update.

Some 74% of all sales stem from the USA, highlights the analyst. On current forecasts, five-year CAGR will be 25% p.a., but Ord Minnett (Morningstar) believes the market is expecting more, getting too excited in advance.

Fair value estimate is $1. Sell.

FORECAST
Ord Minnett forecasts a full year FY24 dividend of 0.00 cents and EPS of 0.30 cents.
Ord Minnett forecasts a full year FY25 dividend of 0.00 cents and EPS of 1.50 cents.

Bell Potter

xx/xx/xxxx

3

xxxxxxxxx xx xxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

27/06/2024

1

Overweight

$2.65

3.52%

Wilsons highlights an impressive 1H and recent trading update by PolyNovo, which defied expectations based on weaker competitor readthroughs.

The broker anticipates higher growth in both the near-term and longer-term, the latter due to growth in ROW markets and a refocus on pipeline development, along with the company's current positioning in the US market.

The Overweight rating is maintained and the target is increased to $2.65 from $2.44 partly due to increases in the broker's US pricing assumptions across the forecast period.

FORECAST
Wilsons forecasts a full year FY24 dividend of 0.00 cents and EPS of 0.90 cents.
Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of 2.40 cents.
Access Stockbroker Research History >

PNV STOCK CHART

FNArena News on PNV

1
Rudi’s View: How To Invest Allan’s $300k, Part 2

Jul 25 2024 - Rudi's View
2
Australian Broker Call *Extra* Edition – Jun 27, 2024

Jun 27 2024 - Daily Market Reports
3
Rudi’s View: More Positives Than Negatives

May 15 2024 - Rudi's View
4
Rudi’s View: Healthcare Under The Scanner

Mar 13 2024 - Rudi's View
5
In Case You Missed It – BC Extra Upgrades & Downgrades – 08-03-24

Mar 08 2024 - Weekly Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
CSL Shares Breaking Free

Jul 23 2024 - Technicals
2
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
3
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
4
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
5
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps
6
Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024 - Small Caps
7
Dr Boreham’s Crucible: Amplia Therapeutics

Jun 05 2024 - Small Caps
8
Is The Long Wait For CSL About To End?

May 30 2024 - Technicals
9
Dr Boreham’s Crucible: Invion

May 13 2024 - Small Caps
10
Dr Boreham’s Crucible: Race Oncology

Apr 09 2024 - Small Caps